Stryker

Phase A — Understand the business

Company Overview

Stryker is a ~$25B-revenue diversified medical-technology company — one of the "big three/four" of orthopaedics and a top-five player across most surgical-equipment categories. Incorporated in Michigan in 1946, successor to a business founded in 1941 by orthopaedic surgeon Dr. Homer Stryker. It sells in ~61 countries, ~56,000 employees (~28,000 US).

How it makes money — two reportable segments (recast Q1 2026):

• MedSurg and Neurotechnology — $15,647M FY2025, 62% of revenue. Four/five sub-businesses: Instruments (surgical power tools, navigation, surgical PPE — $3,183M), Endoscopy (4K camera/communications — $3,807M), Medical (LIFEPAK defibrillators, EMS, patient handling, Vocera comms/AI virtual care — $4,204M), Vascular (stroke + venous thromboembolism, now incl. Inari — $1,968M), Neuro Cranial (skull-base, biosurgery — $2,485M).
• Orthopaedics — $9,469M FY2025, 38% of revenue. Knees ($2,656M), Hips ($1,865M), Trauma & Extremities ($3,948M), plus Mako robotics/enabling tech ("Other" $815M); Spinal Implants ($185M) was divested April 2025.

Customers/channel: Sold mostly directly to surgeons, hospitals and healthcare facilities, supplemented by third-party dealers/distributors. No customer concentration disclosed — a hospital-by-hospital razor/razor-blade model (capital equipment + recurring implants, disposables, service contracts). Contract liabilities of $1,035M are mostly multi-period extended-service contracts. Recurring-services revenue is <10% of sales recognized over time.

Business model in plain terms: an M&A-fed innovation flywheel. Stryker buys category-leading device franchises, plugs them into a best-in-class US hospital sales force, and pulls them through with the Mako robotics razor (place the robot → lock in the implant pull-through for a decade). Growth is "high-end of MedTech" organic (8-10%) compounded by serial bolt-on acquisitions. Capital-allocation priority is explicit and unusual: (1) Acquisitions, (2) Dividends, (3) Buybacks.

Supply Chain

Commercial-layer supply-chain.md is a pointer only (not on disk); mapped from the filings.

Upstream → Stryker → end customer:

• Inputs: titanium/cobalt-chrome alloys, polyethylene, electronic components, polymers, plus contract sterilization services. "Generally readily available from multiple sources; however, certain raw materials are currently sourced from single suppliers". The 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. flags electronic-component shortages (experienced historically) and sole-source suppliers validated under FDA quality-system rules — a regulatory switching cost that makes resourcing slow.
• Manufacturing footprint (named): US — Arizona, California, Florida, Illinois, Indiana, Michigan, Minnesota, New Jersey, Puerto Rico, Tennessee, Texas, Utah, Washington; ex-US — China, France, Germany, Ireland, Mexico, Netherlands, Poland, Switzerland, Turkey. Manufacturing of certain product lines is concentrated in one or more plants/regions — a single-site chokepoint risk the company itself names.
• Sterilization is an outsourced third-party chokepoint (named as a risk category).
• Downstream: direct sales force → hospitals/ASCs/surgeons; plus independent distributors in many ex-US markets ("indirect distribution channels … the main point of contact" — channel risk if they go insolvent or carry competitors).

Chokepoints / single-source dependencies:

1. Single-source raw materials/components validated under FDA QSR — slow to second-source ``.
2. IT systems as a supply-chain node — the March 2026 cyber-attack forced a ~3-week idle production window and hit Q1 gross margin by ~200bps. This is the supply chain's newly-exposed soft spot.
3. Tariff exposure — US tariffs on China/EU goods (2025), partially struck down by the Supreme Court (Learning Resources v. Trump) then re-imposed under Trade Act §122; refund timing uncertain. ~32% of cash now sits offshore.

Competitive Advantages (moats)

Named competitors by line:

• Orthopaedics/robotics: Zimmer Biomet, Johnson & Johnson MedTech, Smith & Nephew (Stryker is 1 of 4 leaders).
• Instruments: Zimmer, Medtronic, J&J MedTech, ConMed.
• Endoscopy: Karl Storz, Olympus, Smith & Nephew, ConMed, Arthrex, STERIS.
• Vascular/Neuro: Medtronic, J&J MedTech, Terumo, Penumbra.
• Medical: Baxter, Zoll, Medline, Ferno.

Durable moats:

1. Mako robotic installed base = switching cost + ecosystem lock-in. Mako in 45+ countries, >1M robotic total-knee procedures and >2M total robotic procedures performed to date. The robot is the razor: once a hospital standardises on Mako, the knee/hip implant pull-through and the multi-year service revenue are sticky. The new Mako 4 + Q-Guidance platform and Mako Shoulder (full US launch Q1 2026) extend the suite into new sub-specialties — widening the moat into shoulder/spine/revision-hip where rivals are thinner.
2. Scale + breadth of the US hospital sales force — the asset acquisitions are plugged into. This is why Stryker can buy a Wright Medical or an Inari and accelerate it.
3. IP estate: ~5,600 US patents + ~9,000 foreign patents.
4. Brand/quality reputation in surgeon preference — a genuine perceived-value moat in implants, where surgeon familiarity and outcomes data are sticky.
5. Regulatory barrier: FDA 510(k)/PMA + EU MDR compliance is a capital and time moat against new entrants.

Bargaining power: Strong over most suppliers (scale buyer), weaker vs. large consolidated hospital systems / GPOs and vs. government single-payers running volume-based procurement (China VBP explicitly named as a price-cutting force). Pricing power is modestly positive (+0.4% price FY2025, +0.3% Q1 2026) — Stryker grows on volume, not price. That is the key moat caveat: it is a volume-and-mix compounder, not a pricing monopoly like Intuitive.

Segments

All figures (FY) and (Q1 2026).

Revenue by segment (FY):

Segment operating income (FY2025, internal measure):

• MedSurg & Neuro: $4,672M op income → ~29.9% segment margin (up from $4,004M FY24).
• Orthopaedics: $2,820M → ~29.8% segment margin (up from $2,591M).
• Consolidated GAAP operating income $4,889M (19.5% reported margin) after $889M corporate, $732M intangible amort, $335M deal charges, $170M impairment.

What moved and why:

• MedSurg is the growth engine — accelerating, now 62% of revenue (was 59% in 2023). Driven by Vascular (+50.6% FY2025, lapping/adding Inari), Neuro Cranial (+16.3%), Endoscopy (+12.3%), Instruments (+12.3%). Inari took Vascular from a $1.2B neurovascular niche to a ~$2.0B peripheral-vascular franchise.
• Orthopaedics is decelerating — only +3.8% cc FY2025, dragged by the Spinal Implants divestiture (-73.9%, sold to Viscogliosi Brothers April 2025). Ex-spine, the ortho "9,284" base grew +10.3% cc — Knees +8.2%, Hips +8.9%, Trauma & Extremities +11.8%. So the headline ortho weakness is portfolio surgery, not demand collapse.

Q1 2026 segment read (the cyber quarter):

• MedSurg & Neuro $3,207M (+5.0% rep, +3.6% cc); Vascular +27.5%; Instruments +9.9%; Medical -4.6%.
• Orthopaedics $2,813M (+0.1% rep, -1.8% cc — spine -98.9%; ex-spine +4.3% cc).
• Segment operating income actually fell YoY: MedSurg op margin 21.8% (was 24.8%), Ortho 30.1% (was 30.4%) — both hit ~190-220bps by idle-production costs from the cyber-attack.

Geography FY2025: US $19,006M (76%), EMEA $3,181M, APAC $2,164M, Other $765M. US-centric (12.2% US growth vs 6.4% intl cc) — a relative insulation from China VBP, but heavy single-country concentration.

---

Phase B — Measure performance

Earnings Result (latest print — Q1 2026, reported Apr 30 2026)

The most important single fact in this dossier: Q1 2026 was a cyber-attack quarter, and it missed badly — but management did not cut full-year guidance.

Reported Q1 2026:

• Net sales $6,020M (+2.6% reported, +1.0% cc, +2.4% organic) — vs ~$6.34B Street expectation. The miss ≈ the $375M of deferred/lost sales from the attack.
• Gross margin 63.3% (−50bps YoY; -200bps from idle-production manufacturing costs, partly offset).
• GAAP operating income $936M (15.5% — up YoY because the prior-year quarter carried a $139M Inari change-of-control charge + $35M impairment).
• Adjusted operating margin 21.1% (−180bps YoY); adjusted diluted EPS $2.60, −8.5% YoY, vs ~$2.98 consensus → ~13% miss.
• GAAP diluted EPS $1.93 (+14.2% — flattered by prior-year charges).

Drivers: Vascular (Inari) and Instruments carried the top line; Medical (-4.6%) and all of Orthopaedics (volume hit) were dragged by the production halt. The whole margin story is the cyber-attack idle time.

Guidance — REAFFIRMED:

• FY2026 organic net-sales growth 8.0–9.5%.
• FY2026 adjusted diluted EPS $14.90–$15.10.
• Management's claim: most of the ~$375M lost Q1 sales are deferred, not lost, and recoverable across Q2–Q4 (orders, not cancellations). This is the entire bull/bear fault line (Lens 12).

Balance-sheet flags:

• Cash $2,878M (down from $4,011M — repaid $1,000M of 3.50% notes in March).
• Inventories $5,419M and rising (+$109M QoQ) — partly cyber-driven WIP build, worth watching for Q2 normalisation.
• Receivables fell to $3,571M (collections strong; +$444M cash from AR).
• Total debt $14,723M; net debt ≈ $11.8B; long-term debt $14,224M, all investment-grade senior unsecured notes laddered to 2050.
• Operating cash flow $581M (up from $250M) — healthy despite the disruption.

Market reaction: stock dipped on the print; SYK is "trading well off its 2026 highs". The market treated it as a one-off but did not award a relief rally — consistent with a name where ~20x forward already assumes the recovery.

Earnings Calls (sentiment trend)

No transcripts on disk; grounded from web call coverage.

• Q1 2026 (Apr 30): tone = "contain, recover, reaffirm." Management leaned hard on order books / demand strength and "operational recovery," framing the attack as timing. Stock dipped intra-call. New recurring phrase: cyber-incident "remediation" and "fully operational across our global manufacturing network."
• Q4 2025 / Q2 2025 (prior calls): confident beat-and-raise cadence — Q2 2025 beat ($3.13 vs $3.07), Q1 2025 beat revenue by 3.2%. The recurring spine through 2025 was Mako momentum, Inari integration, and "high-end of MedTech" organic growth.
• Shift over time: from unbroken beat-and-raise swagger (2024–2025) to a defensive "the franchise is intact, trust the guide" posture in Q1 2026. The thing they stopped saying: nothing about margin expansion this quarter — it became "absorb the idle cost and recover." Sentiment is still constructive but, for the first time in years, on the defensive.

Comps

Peer table — all multiples `` as of June 2026, sourced where noted; n/a where a clean figure was unavailable. Do not treat blanks as zero.

5-year ROE: Stryker ~15% current ROE / ~11.8% ROIC; a clean 5-yr-average ROE per peer is n/a (do not fabricate).

Read: SYK trades at a clear premium to the diversified/ortho cohort (MDT ~13.7x, BSX ~13.2x, ZBH lower) and at a discount to the pure-play robotics monopolist (ISRG ~40.8x). At ~20x forward it sits where a high-quality, mid-single-to-high-single-digit organic compounder with a robotics option usually sits — neither cheap nor euphoric. The premium to Medtronic/Zimmer is earned (faster, cleaner organic growth, better execution track record); the discount to Intuitive is deserved (SYK grows on volume not price, has lower incremental margins, and carries M&A integration risk). Trailing P/E ~36–40x looks scary but is distorted by FY2025's elevated tax/charges — forward is the right lens.

Stock-Price Catalysts (what moves SYK)

Pattern over ~5 years +:

• Total-return tape: $100 invested 12/31/2020 → $151.03 by 12/31/2025 (+51%), vs S&P 500 $196.16 (+96%) and S&P Health Care $148.36 (+48%). SYK tracked healthcare but lagged the broad market — a quality compounder, not a momentum rocket. 2025 was roughly flat ($153.30 → $151.03).
• What the market reacts to:

1. Organic-growth prints vs the 8-10% bar — beat-and-raise quarters (Q1/Q2 2025) lifted it; the Q1 2026 organic miss (2.4%) and the cyber news dragged it.
2. Mako milestones / new-platform launches (Mako 4, Mako Shoulder) — narrative catalysts for the robotics premium.
3. Large M&A — Wright Medical (2020), Vocera (2022), Inari (Feb 2025, $4.9B); deals reset the growth algorithm and are scrutinised for integration/margin.
4. One-off shocks — the March 2026 cyber-attack (Iran-linked group "Handala", ~3-week halt, $375M deferred sales, shareholder lawsuits filed) is the dominant idiosyncratic event on the tape right now.
5. Margin trajectory — the Street rewards the "adjusted-EPS-grows-faster-than-revenue" operating-leverage story; anything that breaks it (idle costs, tariffs) pressures the stock.

Takeaway: SYK is fundamentally an earnings-and-execution stock, not a macro or single-customer stock. It de-rates on organic-growth disappointment and margin scares, re-rates on beat-and-raise + Mako narrative.

---

Phase C — Judge people & books

Management

Kevin A. Lobo — Chair & CEO (age 60). CEO since October 2012, Chair since July 2014 — ~13.5-year tenure.

• Track record (quantified): revenue ~$8B (2012) → $25.1B (2025) — roughly 3x; ~10% organic compounding sustained for a decade. Built Mako (acquired 2013) into the category-defining orthopaedic robotics platform — a genuinely franchise-altering bet that worked.
• Capital allocation = serial disciplined M&A. 55–60+ acquisitions under Lobo. Marquee: MAKO Surgical (2013), Wright Medical ($5.4B EVEnterprise valueWhat it would cost to buy the whole company: its market value plus its debt, minus the cash you would get with it. Often very different from market cap., 2020, extremities), Vocera ($3.1B, 2022, digital care), Inari ($4.9B, Feb 2025, peripheral vascular), plus 2025 bolt-ons (Guard Medical, Advanced Medical Balloons) and the May 2026 AVS deal ($435M + $400M milestones, intravascular lithotripsy). Explicit priority order: M&A > dividends > buybacks.
• Skin in the game / returns: ROE ~15%, ROIC ~11.8% — solid but not spectacular for the sector; the ROIC sits below the ortho peers' implant economics because goodwill-heavy M&A dilutes returns on capital (goodwill $19.2B + intangibles $5.5B = ~53% of $46.3B assets). Insider-ownership figure n/a (no our figures on disk).
• Capital-return discipline: dividends raised every year — $950M (2021) → $1,284M (2025); quarterly dividend $0.88 (Q1 2026, +4.8% YoY). Buybacks essentially dormant — $1,033M remained on a 2015 authorisation, $0 repurchased in Q1 2026 or Q4 2025. Cash goes to deals, not the float.
• Succession set up: Spencer Stiles promoted to President & COO (2021, explicitly to lead M&A growth); Preston W. Wells became CFO in 2025 (succeeding long-time CFO Glenn Boehnlein); new Group Presidents Dylan Crotty (Ortho, 2026) and Andy Pierce (MedSurg). A deep, recently-refreshed bench — Lobo at 60 with a credible internal heir in Stiles.
• Red flags: none material on governance. Combined Chair/CEO role is a mild governance ding. Two officers (Stiles, Fletcher) adopted Rule 10b5-1Rule 10b5-1 planA schedule an insider sets in advance saying when their shares will be sold, so the sales cannot be timed on private news. A sale made OUTSIDE such a plan is a live decision, which is why it carries more information. selling plans in Feb 2026 — routine, small (7,849 and ≤15,952 shares). The goodwill-heavy balance sheet is the structural watch-item, not a scandal.
• Archetype: professional capital-allocator / operator-acquirer (not founder). For this stage — a $25B scaled compounder — that is exactly the right archetype: the edge is repeatable, disciplined M&A integration, and Lobo has proven it across 55+ deals.

Verdict on management: A-grade operators. This is one of MedTech's best capital-allocation machines. The only critique is that the model requires continuous M&A to hit the algorithm, which slowly inflates goodwill and caps ROIC.

Forensic Red Flags

Acting as a forensic analyst across the three statements:

• Revenue recognition: clean and conservative — point-in-time for products, <10% over-time services; policies unchanged. Contract liabilities $1,035M (deferred service revenue) are modest and well-disclosed. No channel-stuffing signature (receivables actually fell in Q1). Low risk.
• Goodwill & intangibles — the real watch-item. Goodwill $19,188M + other intangibles $5,516M = $24.7B, ~53% of $46.3B total assets. This is the price of the M&A model. History shows it can impair: $977M goodwill/asset impairment in FY2024 (the Spinal Implants writedown, incl. a $362M held-for-sale valuation allowance) and $170M in FY2025. Management states no reporting unit is currently at risk and the Q1 2026 reorg (recasting into "Ortho Tech," reallocating $518M goodwill) passed impairment testing. Credible, but a future deal souring would hit here.
• Cash flow vs earnings: healthy — FY2025 operating cash flow $5,044M vs $3,246M net earnings (1.55x conversion); capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. only $761M → FCFFree cash flowCash left after paying to run and maintain the business. Unlike profit, it is hard to flatter with accounting choices. ~$4,283M. Earnings are cash-backed, not accrual-flattered. Low risk.
• Inventory: $5,419M and rising (+$109M QoQ in Q1, partly cyber WIP build). Inventory days are structurally high (implant consignment model — sets sit in hospitals), so elevated inventory is normal, but watch Q2 for normalisation post-attack.
• SBC / non-GAAP gap: the gap between GAAP EPS ($8.40 FY2025) and adjusted EPS ($13.63) is large (~$5.23, ~62% uplift). Drivers: $732M intangible amortisation (real M&A cost added back), $335M deal charges, $173M inventory step-up, $191M structural-optimisation, $170M impairment. SBC itself is modest ($87M/qtr, ~1.4% of sales) — not the flatterer. The amortisation add-back is defensible (non-cash) but inflates the "adjusted" story; a purist should haircut adjusted EPS for recurring deal amortisation. Medium presentation risk, low integrity risk.
• Tax: effective rate 12.4% Q1 2026 / 12.9% FY2025 — low, driven by European operations and IP-transfer discrete items. FY2025 GAAP tax jumped 154% YoY (to $1,268M) on a discrete item, distorting trailing P/E. Sustainable low-teens rate is a known MedTech structure (Ireland/Puerto Rico), not aggressive.
• Leverage: net debt ~$11.8B against ~$8.6B FY2025 adjusted EBITDA `` ≈ ~1.4–2.4x depending on GAAP/adjusted — comfortably investment-grade, ample capacity for the next deal.

Regulatory findings (required sub-section):

• SEC Litigation Releases: None — "No LR found for this company" since 2021-06-22.
• SEC AAERs (accounting/auditing enforcement): None.
• 10-K Item 3 (Legal Proceedings): boilerplate only — "various ongoing proceedings … arising in the normal course of business" (product, labor, tax, IP), cross-referencing Notes 7/11; no specifically-named material litigation disclosed. Stryker carries ongoing recall-related reserves (Rejuvenate/ABG II, LFIT V40, Wright legacy hip products — named in the non-GAAP adjustment definitions), but these are legacy, reserved, and immaterial per-quarter ($10M Q1 2026 recall-related charge).
• Non-SEC / new: the March 2026 cyber-attack has already drawn shareholder lawsuits — a litigation overhang to monitor (securities/derivative claims alleging the incident's materiality and disclosure). No FTC/DOJ/FDA enforcement action surfaced in search beyond routine FDA device regulation. The 2020 Wright Medical deal cleared FTC with divestitures (historical, resolved).
• Net: No material accounting or SEC-enforcement red flags. Verified via SEC EDGAR EFTS (LR, AAER), 10-K Item 3, and web search as of 2026-06-22. The only live legal item is the new cyber-incident shareholder litigation; the only structural accounting watch-item is goodwill (53% of assets) given the impairment history.

---

Phase D — Project & stress-test

Forward Projection (FY2026–FY2028 adjusted diluted EPS)

Built bottom-up from FY2025 actuals + management's reaffirmed FY2026 guide. Output ``; inputs labelled.

Anchors:

• FY2025 adjusted diluted EPS $13.63.
• Management FY2026 guide: organic 8.0–9.5%, adjusted EPS $14.90–$15.10.
• Share count ~386.5M diluted, ~flat (no buybacks; ~+1M/yr dilutionDilutionIssuing new shares, so each existing share owns a smaller slice of the same company. offset by nothing).

Base case — FY2026 adjusted EPS ≈ $14.95. That is +9.7% YoY — the recovery + algorithm.

• FY2027 ≈ $16.6.
• FY2028 ≈ $18.4.

Bull FY2026 ≈ $15.20. Bear FY2026 ≈ $13.9.

Key swing factors: (1) cyber-sales recovery rate (timing vs permanent loss); (2) tariff pass-through; (3) Mako Shoulder/Trauma share gains; (4) M&A accretion pace; (5) FX (a tailwind in Q1 at +1.6%).

Per --watchlist rules, no our model create was run (breadth mode logs no Brier forecast). The trackable base call to log later: "SYK FY2026 adjusted diluted EPS ≥ $14.90," p≈0.62, resolves 2026-12-31 — conditioned on the recovery thesis holding.

Bull vs Bear

Bull case. Stryker is one of MedTech's highest-quality compounders, and the Q1 cyber-attack handed the market a rare, mechanical reason to de-rate a structurally great franchise. The organic engine (8-10%, volume-led, across two diversified $9-16B segments) is intact — ex-spine, ortho still grew double-digits cc in 2025. The Mako razor (45+ countries, 2M+ procedures, Mako 4 + Shoulder extending the suite) locks in a decade of implant pull-through and is the durable moat rivals can't cheaply replicate. Capital allocation is best-in-class: 55+ disciplined deals under Lobo turned $8B into $25B, with Inari ($2B vascular franchise) and AVS adding fresh high-growth legs. Management reaffirmed full-year EPS despite the miss — a tell that the order book is real and the $375M is timing. If recovery plays out, FY2026 EPS lands ~$15 (+10%), FY2027 ~$16.6, and a high-teens-forward-multiple holds → mid-teens annual total return with downside protection from the quality + dividend. Contrarian read: the market is treating a one-time IT event as if it dented the franchise; it didn't.

Bear case (permanent-impairment risks).

1. The recovery is not fully timing. If a chunk of the $375M in deferred elective/ortho procedures permanently leaks to Zimmer/J&J/Smith+Nephew during the 3-week outage (surgeons switched trays and stayed), the FY2026 guide is cut, the "beat-and-raise compounder" narrative breaks, and a ~20x forward multiple compresses fast. Med-device share, once a surgeon re-standardises, is sticky against you too.
2. Margin/valuation mismatch. SYK grows on volume, not price (+0.3-0.4% pricing), so it has no pricing-power buffer against tariff cost inflation (named, China/EU, re-imposed under Trade Act §122) or idle-cost shocks. At ~20x forward + ~20x EV/EBITDA, the stock prices flawless execution; any organic deceleration toward MedTech-average (it lagged the S&P by ~45pts over 5 years even while executing well) leaves little margin of safety.
3. Goodwill-funded growth has a ceiling. $24.7B goodwill+intangibles (53% of assets), ROIC only ~11.8%, and a $977M impairment as recently as FY2024 (spine). The algorithm requires ever-larger deals; if M&A targets get expensive or a deal sours, both growth and the balance sheet take the hit.

Pre-mortem (18 months out, thesis broke): It's late 2027. Q1 2026's lost procedures never fully came back — ortho organic settled at ~5-6%, below the 8-9% promise. Tariffs and the cyber-remediation overhang shaved ~150bps of margin, so adjusted EPS grew high-single-digits not low-double, and the Street re-rated SYK from ~20x to ~16x forward on "it's a good-not-great 6% grower." Add a securities-litigation settlement from the cyber lawsuits and a soft bolt-on that needed a writedown. The stock did nothing for two years while ISRG and BSX compounded.

Are multiples too high? Not egregiously — ~20x forward for a ~9% EPS compounder is fair-to-slightly-full (PEG ~2.1). It is not cheap. The asymmetry is modest: you're paying a quality premium and underwriting the recovery.

Contrarian view (what the market refuses to see): Possibly that the cyber-attack is a positive catalyst in disguise — it created a clean entry on a franchise that rarely goes on sale, and 2026 EPS comps become trivially beatable once the air-pocket laps. The other side: the market may be under-pricing how little pricing power Stryker has in a tariff/VBP world relative to its multiple.

Devil's Advocate (short-seller)

Dismantling the bull case:

• Where is revenue concentrated, and what breaks it? ~76% US — a single-geography, single-payer-policy bet. Domestic hospital capex cycles, US elective-procedure volumes, and US reimbursement changes hit ~three-quarters of the business at once. And within ortho, the implant business depends on surgeon preference — exactly what a 3-week supply outage (cyber) puts at risk if surgeons trial a competitor's tray and like it.
• Why the moat is weaker than bulls think: Mako is a real moat in knees/hips, but it's an installed-base moat, not a recurring-toll monopoly like Intuitive's da Vinci (where every procedure burns Intuitive instruments at ~70%+ gross margin). Stryker still has to sell the implant against Zimmer/J&J every cycle, on volume with near-zero pricing power. The robotics premium baked into ~20x forward may be over-credited.
• Most dangerous competitor bulls underestimate: J&J MedTech (Velys robotics + Monarch + DePuy implants + balance-sheet firepower) and a resurgent Zimmer Biomet (ROSA robotics) — both can subsidise robot placements to defend implant share. In vascular, Medtronic, Penumbra, Terumo are formidable, and the Inari thesis (VTE) faces reimbursement and competitive pressure.
• Worst capital-allocation moves: the Spinal Implants franchise destroyed value — written down ($977M FY2024 incl. valuation allowance) and dumped to Viscogliosi for ~$245M deferred-heavy consideration. That's an admission a prior buildout failed. Goodwill is 53% of assets and ROIC is sub-12% — the M&A machine manufactures growth at the cost of return on capital.
• What must hold for today's price: 8-9% organic every year, full cyber-recovery, margin expansion resuming, no large impairment, continuous accretive M&A, and the multiple staying ~20x. That's a lot of "ands."
• If growth disappoints 20-30% (organic to ~6%): EPS growth drops to high-single-digits, PEG blows out, and a de-rate to ~15-16x forward → ~20-25% downside from ~$308 toward ~$235-250.
• Single scenario that permanently impairs: a second major operational failure (cyber, FDA quality consent decree, or a flagship recall) that durably cedes ortho share — med-device share shifts are slow to win and slow to win back. Plausibility: low-to-moderate, but the cyber-attack just proved the operational tail is non-zero.

Management Questions (ordered by information value)

1. Of the ~$375M in Q1 2026 sales lost to the cyber-attack, how much is genuinely deferred (recoverable orders) vs permanently lost (procedures done on a competitor's system), and what evidence (re-order rates, surgeon retention by account) do you have through Q2?
2. Did the 3-week outage cause any measurable loss of orthopaedic implant share to Zimmer/J&J/Smith+Nephew at affected accounts, and have those accounts fully returned?
3. With ~0.3-0.4% annual pricing and named tariff exposure, how do you protect adjusted operating margin through 2026-2027 without pricing power — what's the specific cost-offset plan?
4. Goodwill + intangibles are ~53% of assets and ROIC is ~11.8%; at what point does the M&A model dilute returns on capital below your cost of capital, and how do you think about the ceiling?
5. The Spinal Implants build-and-divest cycle destroyed ~$1B of value — what changed in your M&A diligence and portfolio-review process as a result?
6. Mako is an installed-base moat, not a per-procedure toll like da Vinci — what is the actual recurring/consumable revenue attach rate per Mako, and how do you make the robot itself a recurring economic engine?
7. How do Mako 4, Mako Shoulder, and robotic revision-hip change your implant share trajectory over the next 3 years, quantitatively?
8. What is the integration status and revenue/margin trajectory of Inari, and does the peripheral-vascular thesis still support the $4.9B price given competitive and reimbursement dynamics?
9. Capital allocation is M&A > dividends > buybacks — at ~20x forward and with buybacks dormant, what deal size/return hurdle would make you prefer repurchases instead?
10. What is your remediation roadmap and incremental cybersecurity spend run-rate post-attack, and how should we model its margin impact?
11. ~76% of revenue is US — what is the deliberate plan (and risk appetite) to diversify geographically, and how do you view China VBP exposure?
12. Where are you on EU MDR compliance (transition through Dec 2028), and what is the residual cost and product-availability risk?
13. Succession: Spencer Stiles as President/COO — what is the board's timeline and the explicit case for an internal vs external next CEO?
14. What recurring-amortisation-adjusted EPS do you consider the "true" earnings power, given the ~$5/share GAAP-to-adjusted gap is largely deal amortisation?
15. What single internal metric, if it deteriorated, would most change your confidence in the 8-9.5% organic algorithm over the next three years?

---